Key Points
- Insider buying: Alignment Healthcare insider Mark Kent bought 14,848 shares at an average price of $13.31, totaling about $197,627. The purchase was disclosed in an SEC filing.
- Recent performance: ALHC opened at $13.64, well below its 50-day and 200-day moving averages, though it remains above its 52-week low of $11.63. The company has a market cap of $2.82 billion.
- Business and outlook: Alignment Healthcare recently beat quarterly EPS and revenue estimates, with revenue up 33.3% year over year. Analysts currently have a consensus rating of Moderate Buy and an average price target of $24.30.
Alignment Healthcare, Inc. (NASDAQ:ALHC - Get Free Report) insider Mark Kent purchased 14,848 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The stock was acquired at an average cost of $13.31 per share, with a total value of $197,626.88. Following the completion of the acquisition, the insider directly owned 14,848 shares of the company's stock, valued at $197,626.88. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Alignment Healthcare Stock Performance
Shares of ALHC opened at $13.64 on Wednesday. The stock has a 50 day moving average price of $18.57 and a 200 day moving average price of $19.38. The company has a quick ratio of 1.58, a current ratio of 1.58 and a debt-to-equity ratio of 1.56. The company has a market capitalization of $2.82 billion, a price-to-earnings ratio of 151.56, a price-to-earnings-growth ratio of 1.86 and a beta of 1.14. Alignment Healthcare, Inc. has a 52-week low of $11.63 and a 52-week high of $23.87.
Alignment Healthcare (NASDAQ:ALHC - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.04. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.22 billion. Alignment Healthcare had a return on equity of 11.50% and a net margin of 0.47%.The firm's quarterly revenue was up 33.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.05) earnings per share. Research analysts predict that Alignment Healthcare, Inc. will post 0.19 EPS for the current fiscal year.
Institutional Investors Weigh In On Alignment Healthcare
Large investors have recently modified their holdings of the stock. Summit Securities Group LLC purchased a new stake in shares of Alignment Healthcare during the fourth quarter worth approximately $26,000. Parallel Advisors LLC raised its stake in shares of Alignment Healthcare by 87.7% during the fourth quarter. Parallel Advisors LLC now owns 1,654 shares of the company's stock worth $33,000 after purchasing an additional 773 shares during the last quarter. Larson Financial Group LLC purchased a new stake in shares of Alignment Healthcare during the third quarter worth approximately $33,000. First Horizon Corp purchased a new stake in shares of Alignment Healthcare during the fourth quarter worth approximately $39,000. Finally, GAMMA Investing LLC raised its stake in shares of Alignment Healthcare by 83.8% during the fourth quarter. GAMMA Investing LLC now owns 2,165 shares of the company's stock worth $43,000 after purchasing an additional 987 shares during the last quarter. Hedge funds and other institutional investors own 86.19% of the company's stock.
Analyst Ratings Changes
Several research firms have recently weighed in on ALHC. UBS Group increased their price objective on Alignment Healthcare from $21.00 to $22.00 and gave the company a "neutral" rating in a report on Friday, May 1st. JPMorgan Chase & Co. increased their price objective on Alignment Healthcare from $23.00 to $26.00 and gave the company an "overweight" rating in a report on Thursday, February 5th. Wall Street Zen raised Alignment Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, May 9th. Wolfe Research began coverage on Alignment Healthcare in a report on Friday, April 17th. They issued an "outperform" rating and a $24.00 price objective for the company. Finally, Weiss Ratings raised Alignment Healthcare from a "sell (d-)" rating to a "hold (c-)" rating in a report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $24.30.
View Our Latest Analysis on ALHC
Alignment Healthcare Company Profile
(
Get Free Report)
Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.
At the core of Alignment Healthcare's approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
